Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Sarepta Therapeutics stock
Learn how to easily invest in Sarepta Therapeutics stock.
Sarepta Therapeutics Inc is a biotechnology business based in the US. Sarepta Therapeutics shares (SRPT) are listed on the NASDAQ and all prices are listed in US Dollars. Sarepta Therapeutics employs 840 staff and has a trailing 12-month revenue of around $835.2 million.
How to buy shares in Sarepta Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SRPT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Sarepta Therapeutics stock price (NASDAQ: SRPT)Use our graph to track the performance of SRPT stocks over time.
Sarepta Therapeutics shares at a glance
|Latest market close||$109.94|
|52-week range||$61.28 - $120.23|
|50-day moving average||$105.35|
|200-day moving average||$83.94|
|Wall St. target price||$130.74|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-4.29|
Buy Sarepta Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Sarepta Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sarepta Therapeutics price performance over time
|1 week (2022-09-27)||1.49%|
|1 month (2022-09-02)||0.51%|
|3 months (2022-07-01)||45.21%|
|6 months (2022-04-04)||28.40%|
|1 year (2021-10-04)||16.14%|
|2 years (2020-10-02)||-18.44%|
|3 years (2019-10-04)||24.58%|
|5 years (2017-10-04)||120.85%|
Is Sarepta Therapeutics stock undervalued or overvalued?
Valuing Sarepta Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sarepta Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sarepta Therapeutics's PEG ratio
Sarepta Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 159.25. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sarepta Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Sarepta Therapeutics financials
|Revenue TTM||$835.2 million|
|Gross profit TTM||$-165,844,000|
|Return on assets TTM||-9.51%|
|Return on equity TTM||-83.63%|
|Market capitalisation||$9.6 billion|
TTM: trailing 12 months
Sarepta Therapeutics share dividends
We're not expecting Sarepta Therapeutics to pay a dividend over the next 12 months.
Have Sarepta Therapeutics's shares ever split?
Sarepta Therapeutics's shares were split on a 1:6 basis on 12 July 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sarepta Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Sarepta Therapeutics shares which in turn could have impacted Sarepta Therapeutics's share price.
Sarepta Therapeutics share price volatility
Over the last 12 months, Sarepta Therapeutics's shares have ranged in value from as little as $61.28 up to $120.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sarepta Therapeutics's is 1.193. This would suggest that Sarepta Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Sarepta Therapeutics overview
Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Sarepta Therapeutics in the news
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Best Stocks In The IBD 50 Can Be Found By Using This Simple Tool
Frequently asked questionsWhat percentage of Sarepta Therapeutics is owned by insiders or institutions?
Currently 4.396% of Sarepta Therapeutics shares are held by insiders and 83.625% by institutions. How many people work for Sarepta Therapeutics?
Latest data suggests 840 work at Sarepta Therapeutics. When does the fiscal year end for Sarepta Therapeutics?
Sarepta Therapeutics's fiscal year ends in December. Where is Sarepta Therapeutics based?
Sarepta Therapeutics's address is: 215 First Street, Cambridge, MA, United States, 02142 What is Sarepta Therapeutics's ISIN number?
Sarepta Therapeutics's international securities identification number is: US8036071004 What is Sarepta Therapeutics's CUSIP number?
Sarepta Therapeutics's Committee on Uniform Securities Identification Procedures number is: 002346104
More guides on Finder
Best renewable energy stocks for 2022
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
The best dividend stocks for 2022
Our list of 10 dividend stocks to watch in 2022.
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Ask an Expert